Patients With Inflammatory Bowel Disease Are At Increased Risk Of Respiratory Syncytial Virus Infections post-SARS-CoV2 Infection: A Propensity-Matched Cohort Analysis.

IF 3 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Clinical and Translational Gastroenterology Pub Date : 2025-03-27 DOI:10.14309/ctg.0000000000000840

Saqr Alsakarneh, Oscar Ramirez Ramirez, Mary S Hayney, Jana G Hashash, Francis A Farraye, Freddy Caldera

{"title":"Patients With Inflammatory Bowel Disease Are At Increased Risk Of Respiratory Syncytial Virus Infections post-SARS-CoV2 Infection: A Propensity-Matched Cohort Analysis.","authors":"Saqr Alsakarneh, Oscar Ramirez Ramirez, Mary S Hayney, Jana G Hashash, Francis A Farraye, Freddy Caldera","doi":"10.14309/ctg.0000000000000840","DOIUrl":null,"url":null,"abstract":"Introduction: Patients with inflammatory bowel disease (IBD) are at an increased risk of infections. Before the COVID-19 pandemic, respiratory syncytial virus (RSV) followed predictable seasonal patterns, which have been recently disrupted. This study aimed to investigate whether SARS-CoV2 infection is associated with an increased risk of RSV infection in patients with IBD compared to those without a history of SARS-CoV-2.Methods: This retrospective cohort study used the TriNetX database to identify patients aged ≥18 years with IBD and SARS-CoV2 (IBD-SARS-CoV2 cohort) during the 2022 and 2023 RSV seasons. A 1:1 propensity score matching was used to compare patients with IBD but no history of SARS-CoV2 (IBD non-SARS-CoV2 cohort).Results: In the 2022 IBD-SARS-CoV2 cohort (mean age: 53.7 ± 17.6; 59% female; 77% white), the RSV infection risk was 0.47%, higher than 0.19% in the matched IBD non-SARS-CoV2 cohort (aOR: 2.4; 95% CI: 1.5-3.6). The risk was highest 30-60 days post-SARS-CoV2 infection (aOR: 2.9; 95% CI: 1.7-4.9), particularly in those aged ≥60 years (aOR: 2.5; 95% CI: 1.3-4.5). The use of systemic corticosteroids (aOR: 2.3; 95% CI: 1.1-4.6) or immune-modifying therapies (aOR: 3.9; 95% CI: 2-7.1) was associated with higher RSV risk. Similar trends were observed during the 2023 RSV season, with no significant differences in RSV-related hospitalizations.Discussion: Adults with IBD have a higher risk of RSV following SARS-CoV2 infection, particularly those receiving steroids or immune therapies. SARS-CoV2 may have contributed to the recent RSV surge in this population, warranting further research.","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.14309/ctg.0000000000000840","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Patients with inflammatory bowel disease (IBD) are at an increased risk of infections. Before the COVID-19 pandemic, respiratory syncytial virus (RSV) followed predictable seasonal patterns, which have been recently disrupted. This study aimed to investigate whether SARS-CoV2 infection is associated with an increased risk of RSV infection in patients with IBD compared to those without a history of SARS-CoV-2.

Methods: This retrospective cohort study used the TriNetX database to identify patients aged ≥18 years with IBD and SARS-CoV2 (IBD-SARS-CoV2 cohort) during the 2022 and 2023 RSV seasons. A 1:1 propensity score matching was used to compare patients with IBD but no history of SARS-CoV2 (IBD non-SARS-CoV2 cohort).

Results: In the 2022 IBD-SARS-CoV2 cohort (mean age: 53.7 ± 17.6; 59% female; 77% white), the RSV infection risk was 0.47%, higher than 0.19% in the matched IBD non-SARS-CoV2 cohort (aOR: 2.4; 95% CI: 1.5-3.6). The risk was highest 30-60 days post-SARS-CoV2 infection (aOR: 2.9; 95% CI: 1.7-4.9), particularly in those aged ≥60 years (aOR: 2.5; 95% CI: 1.3-4.5). The use of systemic corticosteroids (aOR: 2.3; 95% CI: 1.1-4.6) or immune-modifying therapies (aOR: 3.9; 95% CI: 2-7.1) was associated with higher RSV risk. Similar trends were observed during the 2023 RSV season, with no significant differences in RSV-related hospitalizations.

Discussion: Adults with IBD have a higher risk of RSV following SARS-CoV2 infection, particularly those receiving steroids or immune therapies. SARS-CoV2 may have contributed to the recent RSV surge in this population, warranting further research.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Translational Gastroenterology GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

7.00

自引率

0.00%

发文量

114

审稿时长

16 weeks

期刊介绍： Clinical and Translational Gastroenterology (CTG), published on behalf of the American College of Gastroenterology (ACG), is a peer-reviewed open access online journal dedicated to innovative clinical work in the field of gastroenterology and hepatology. CTG hopes to fulfill an unmet need for clinicians and scientists by welcoming novel cohort studies, early-phase clinical trials, qualitative and quantitative epidemiologic research, hypothesis-generating research, studies of novel mechanisms and methodologies including public health interventions, and integration of approaches across organs and disciplines. CTG also welcomes hypothesis-generating small studies, methods papers, and translational research with clear applications to human physiology or disease. Colon and small bowel Endoscopy and novel diagnostics Esophagus Functional GI disorders Immunology of the GI tract Microbiology of the GI tract Inflammatory bowel disease Pancreas and biliary tract Liver Pathology Pediatrics Preventative medicine Nutrition/obesity Stomach.